# Plain Language Summary: No Tax Breaks for Drug Ads Act

Right now, pharmaceutical companies can deduct the cost of advertising prescription drugs as a business expense on their taxes, which reduces the amount of taxes they owe. This bill would eliminate that tax break. Specifically, drug companies would no longer be able to write off the money they spend on ads aimed directly at regular people—the kind of ads you see on TV, in magazines, on social media, or on billboards telling you to "ask your doctor about" a particular medication.

The bill targets what's called "direct-to-consumer advertising," which means ads created to reach patients rather than doctors or healthcare professionals. This includes any ads in newspapers and magazines, radio and television commercials, direct mail, billboards, and digital advertising on the internet and social media platforms. The tax deduction would be denied for all these types of promotional spending on prescription drugs.

The practical effect would be that pharmaceutical companies would have less financial incentive to spend money on consumer-facing drug advertising, since they can't reduce their tax bill by doing so. This could potentially lead to fewer drug ads in your daily life, though companies might still advertise if they believe it's worth the full cost. The bill would also generate additional tax revenue for the government since drug companies would owe more in taxes. Supporters argue this could help reduce drug prices indirectly by lowering companies' marketing costs, while critics might worry it could affect how much information patients receive about available medications.

No Tax Breaks for Drug Ads Act

Slotkin, Elissa

No Tax Breaks for Drug Ads ActThis bill disallows any tax deduction for expenses relating to direct-to-consumer advertising of prescription drugs.